Xeris Biopharma Holdings, Inc. (XERS) › Operating IncomeXeris Biopharma Holdings, Inc. (XERS) — Operating IncomeAnnual figures by period end, from SEC filings.2020-12-31: -$83.55M2021-12-31: -$115.16M2022-12-31: -$81.94M2023-12-31: -$44.01M2024-12-31: -$33.65M2025-12-31: $24.90M$24.90M2020-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31$24.90M—2026-03-02From 2025-01-012024-12-31-$33.65M—2026-03-02From 2024-01-012023-12-31-$44.01M—2026-03-02From 2023-01-012022-12-31-$81.94M—2025-03-06From 2022-01-012021-12-31-$115.16M—2024-03-06From 2021-01-012020-12-31-$83.55M—2022-03-11From 2020-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)